Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 5 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 14th May, paid: 9th Jul more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -14.6%

FINANCIAL BRIEF: For the three months ended 31 March 2015, GlaxoSmithKline plc revenues increased less than 1% to L5.62B. Net income increased from L668M to L8.09B. Revenues reflect Consumer Healthcare segment increase of 23% to L1.38B, Vaccines segment increase of 7% to L699M, Consumer Healthcare segment increase of 23% to L1.38B, VIIV Health care segment increase of 43% to L446M, Vaccines segment increase of 7% to L699M. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: 15.4
(+5.41% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +5.9% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
27 brokers Broker Consensus Trend
Broker Recommendations for GlaxoSmithKline
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 1 6 14 6 2

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Jo Walton , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , First Global Kavita Thomas , Nomura Securities , Seymour Pierce , Panmure Gordon Savvas Neophytou , Natixis Philippe Lanone Jean-Jacques Le Fur , Davy , Macquarie Research , Societe Generale Florent Cespedes , WestLB Equity Markets , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Hamburger Sparkasse (HASPA) Marco Gunther , Kepler Cheuvreux Sheela Sharma , Charles Stanley Rae Ellingham , Cenkos Securities Navid Malik , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

GlaxoSmithKline plc. (GSK) is a healthcare company. GSK develops pharmaceutical, vaccine and consumer healthcare products. The pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The vaccines business produces paediatric and adult vaccines against a range of infectious diseases. GSK’s Consumer Healthcare business is structured around four categories: Total Wellness, Oral Care, Nutrition and Skin Health. For Pharmaceuticals and Vaccines, GSK operates in geographical segments that combine these two businesses, namely United States Pharmaceuticals and Vaccines, Europe Pharmaceuticals and Vaccines, Emerging Markets and Asia Pacific (EMAP) Pharmaceuticals and Vaccines, and Japan Pharmaceuticals and Vaccines. Its Consumer Healthcare business functions as a global unit, as does ViiV Healthcare, a human immunodeficiency virus (HIV) company founded by GSK along with Pfizer and Shionogi. In addition, it owns the biological conjugation platform.

Directors: Andrew Witty (CEO) 50, Simon Dingemans (CFO) 51, Moncef Slaoui (CEX) 55, Roger Connor (CEX) , Shah Abbas Hussain (CEX) 49, Patrick Vallance (CEX) , Emma Walmsley (CEX) , Daniel Troy (SVP) , Claire Thomas (SVP) , Bill Louv (SVP) , Philip Hampton (NEC) 61, Roy Anderson (NID) 67, Stephanie Burns (NID) 60, Stacey Cartwright (NID) 51, Lynn Elsenhans (NID) 58,

No. of Employees: 98,702 No. of Shareholders: 139,535

Last Annual December 31st, 2014
Last Interim March 31st, 2015
Shares in Issue 4,866,207,704
Free Float 4.79bn (98.5%)

Address 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom
Web http://www.gsk.com
Phone +44 20 80475000
Contact ()
Auditors PricewaterhouseCoopers LLP

GSK Share Price Performance GSKQuote
14.0  1.0%
Traded 5:08pm · Minimum 15 min delayed · NMS: 1.50k

Latest GSK News Announcements (delayed)

Upcoming GSK Events
Wednesday 29th July, 2015
Q2 2015 GlaxoSmithKline PLC Earnings Release
Wednesday 28th October, 2015
Q3 2015 GlaxoSmithKline PLC Earnings Release
Monday 8th February, 2016 (estimate)
Q4 2015 GlaxoSmithKline PLC Earnings Release
Friday 6th May, 2016 (estimate)
GlaxoSmithKline PLC Annual Shareholders Meeting

Recent ↓
Wednesday 13th May, 2015
Dividend For GSK
Wednesday 13th May, 2015
Dividend For GSK.BA
Thursday 7th May, 2015
GlaxoSmithKline PLC Annual Shareholders Meeting
Wednesday 6th May, 2015
Q1 2015 GlaxoSmithKline PLC Investor Event
Wednesday 6th May, 2015
Q1 2015 GlaxoSmithKline PLC Pre-Recorded Earnings Presentation
Wednesday 6th May, 2015
Q1 2015 GlaxoSmithKline PLC Earnings Release
Wednesday 18th February, 2015
Dividend For GSK
Wednesday 18th February, 2015
Dividend For GSK.BA
Wednesday 4th February, 2015
Q4 2014 GlaxoSmithKline PLC Earnings Call
Wednesday 4th February, 2015
Q4 2014 GlaxoSmithKline PLC Earnings Release

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy GSK

Access GSK Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis